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Background-—Despite variations in the prevalence of cardiovascular disease and related risk factors among US Hispanic/Latino
adults of diverse backgrounds, there is little information on whether disparities exist in the use of medications for the primary and
secondary prevention of cardiovascular disease. We examined the prevalence of statin and aspirin use among diverse US
Hispanic/Latino adults at high cardiovascular risk.
Methods and Results-—A multicenter population-based study, the Hispanic Community Health Study/Study Of Latinos, included a
total of 16 415 participants of Mexican, Puerto Rican, Cuban, Dominican, South American, and Central American backgrounds who
were aged 18 to 74 years and enrolled between March 2008 and June 2011. Our analyses were limited to 4139 participants
considered to be at high cardiovascular risk. Age-adjusted prevalence of statin and aspirin use was 25% and 44%, respectively,
overall but varied by Hispanic/Latino background among those at high cardiovascular risk; statin use was significantly higher
(P<0.001) among adults of Puerto Rican (33%) and Dominican (28%) backgrounds compared with adults of other backgrounds
(Mexican, 24%; Cuban, 22%; Central American, 20%; South American, 22%). There was no difference in aspirin use. After adjusting
for health insurance coverage, the difference in prevalence of statin use was substantially reduced among participants with a
Puerto Rican background, from an odds ratio of 1.73 (95% CI 1.30–2.31) to 1.30 (95% CI 0.97–1.75), and with a Dominican
background, from an odds ratio of 1.45 (95% CI 1.04–2.02) to 1.07 (95% CI 0.75–1.52), in comparison to their counterparts.
Conclusions-—Among Hispanic/Latino adults of diverse backgrounds, statin use was more prevalent among adults with Puerto
Rican and Dominican backgrounds at high cardiovascular risk. These differences in statin use were explained, in part, by
differences in insurance coverage. These findings have important implications for the prevention of disparities in cardiovascular
outcomes within the growing US Hispanic/Latino population. ( J Am Heart Assoc. 2016;5:e002905 doi: 10.1161/
JAHA.115.002905)
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C ardiovascular medications such as statins and aspirin arewidely used in the United States1 and are critical for
primary and secondary prevention of cardiovascular disease
(CVD),2–5 which is increasingly common in the growing and
aging US Hispanic/Latino population. Despite evidence of
disparities in CVD and CVD risk factors, including hyperc-
holesterolemia, among adults from the diverse Hispanic/
Latino groups that compose the US Hispanic/Latino popula-
tion,6 current information on use of medications for the
prevention of CVD, including statins and aspirin, is limited.
Despite the benefits of statins and aspirin for the primary
and secondary prevention of CVD among adults at high
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cardiovascular risk, previous analyses have documented racial
and ethnic disparities in their use in the United States.7,8
These prior analyses, however, aggregated Hispanic/Latino
participants into 1 group and thus did not examine the use of
statins and/or aspirin by Hispanic/Latino background. Dis-
parities in the use of preventive cardiovascular medications
may be an important but overlooked contributor to observed
disparities in CVD6 within the diverse Hispanic/Latino pop-
ulation in the United States.
The study used data from the landmark Hispanic Commu-
nity Health Study/Study of Latinos (HCHS/SOL) to examine
prevalence of cardiovascular medication use among diverse
US Hispanic/Latino adults at high cardiovascular risk.
Sociodemographic, acculturation, and access-to-care factors
associated with cardiovascular medication use were also
examined.
Methods
Participants
The HCHS/SOL is a population-based cohort study devised to
estimate the prevalence of CVD risk factors and to examine
the prospective relationship between risk factors and disease
outcomes among persons of diverse Hispanic/Latino back-
grounds. It included participants of Cuban, Dominican,
Mexican, Puerto Rican, Central American, and South American
origins who were recruited from community areas surrounding
4 field centers in the Bronx, New York; Chicago, Illinois;
Miami, Florida; and San Diego, California, between March
2008 and June 2011. A stratified, multistage, area probability
sample of households was obtained to screen candidates for
eligibility. Of 39 384 persons who were screened and
selected and who met the eligibility criteria, 16 415 were
enrolled for the study. The sample design, cohort selection,
and study implementation were described previously.9 The
current analyses excluded 911 participants who were missing
information on CVD and 590 participants who did not self-
identify as any of the 6 aforementioned Hispanic/Latino
groups (Figure 1). Consequently, the analytic sample
(n=4136) included data from 14 914 participants. Institu-
tional review boards at each participating institution approved
the protocol, and all participants provided written informed
consent.
Data
Data were collected during a baseline examination conducted
at examination centers located at each field site and included
biological measures, interviewer-administered questionnaires,
and a medication inventory.
Body mass index was calculated as weight in kilograms
divided by height in meters squared. After a 5-minute rest
period, 3 seated blood pressure measurements were
Figure 1. Flowchart of participants at high cardiovascular risk who were included in the HCHS/SOL
sample. CHD indicates coronary heart disease; CV, cardiovascular; HCHS/SOL, Hispanic Community Health
Study/Study of Latinos; PVD, peripheral vascular disease.
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obtained, and the second and third readings were averaged.
Blood samples were collected according to standardized
protocols and analyzed for total serum cholesterol, plasma
glucose, high-density lipoprotein, low-density lipoprotein, and
hemoglobin A1c levels.
Information was obtained by questionnaires on demo-
graphic factors, socioeconomic status (education and
income), proxy measures of cigarette smoking, medical
history, and insurance status. Acculturation was also
assessed using a modified version of the Short Acculturation
Scale for Hispanics, which captured the degree of adaptation
to new physical, cultural, social, and economic environments;
proxy measures of acculturation (years of residence in the
United States, nativity, and language preference) were also
assessed.9 Insurance status was derived based on responses
to the question, “What type of health insurance or health care
coverage do you have?” Responses included the following 4
categories: none, private (employer-sponsored or individual
plan), public (Medicare, Medicaid, or military or US Depart-
ment of Veterans Affairs), or other.
Participants at high cardiovascular risk were defined as
those who reported ever being diagnosed with coronary heart
disease (CHD; myocardial infarction) or a CHD risk equivalent
(stroke, peripheral vascular disease, heart failure, and/or
diabetes). The Adult Treatment Panel III guidelines were used
to derive our definition of high cardiovascular risk. Partic-
ipants with CHD or a CHD risk equivalent were considered to
be at highest risk (10-year risk >20%) for developing a
cardiovascular event.10 Prevalent CVD was defined as self-
reported history of CHD (myocardial infarction, coronary
bypass surgery, balloon angioplasty, or stent placement in
coronary arteries) or stroke. As illustrated in Figure 1, our
analytic sample was restricted to 4136 participants defined as
having high cardiovascular risk, which included participants
with and without prevalent CVD.
Major CVD risk factors were based on current guidelines.
Hypertension was defined as systolic blood pressure of
≥140 mm Hg, diastolic blood pressure of ≥90 mm Hg, or
receipt of medication for hypertension. Uncontrolled hyper-
cholesterolemia was defined as total cholesterol ≥240 mg/
dL, high-density lipoprotein cholesterol <40 mg/dL, or low-
density lipoprotein cholesterol ≥160 mg/dL. Obesity was
defined as a body mass index ≥30, calculated as weight in
kilograms divided by height in meters squared. Diabetes
mellitus was defined as fasting glucose ≥126 mg/dL, 2-hour–
postload plasma glucose ≥200 mg/dL, hemoglobin A1c
≥6.5%, use of diabetes medications, or self-reported history
of diabetes.
Participants were instructed to bring all prescription and
nonprescription medications taken in the past month to the
study center at the time of their physical examination.
Cardiovascular medication use was defined as the use of at
least 1 statin or aspirin medication. We defined statin
medication use as the use of at least 1 statin (3-hydroxy-3-
methyglutaryl coenzyme A reductase inhibitors) and aspirin
use as the use of at least 1 aspirin-containing product (that
was not restricted by aspirin indication). We also examined
the concurrent use of at least 1 statin and 1 aspirin
product.
Statistical Analysis
All reported values (prevalence and odds ratio [OR]) were
weighted to adjust for sampling probability and nonresponse.9
Descriptive statistics provided age-adjusted estimates (based
on the mean age of our analytic sample) for the prevalence of
each variable overall and were stratified by Hispanic/Latino
background group. Survey-specific procedures were used to
compute 95% CIs to account for the 2-stage sampling design,
stratification, and clustering. Prevalence of statin and aspirin
use was estimated for the sample as a whole and separately
within each of the Hispanic/Latino background groups.
Comparisons across Hispanic/Latino background groups
were performed using the Wald chi-square statistic.
Multivariable logistic regression was used to model
differences in the prevalence of statin use among those with
high CVD risk. Multivariable multistage logistic regression was
adjusted for demographic and clinical factors in model 1; for
socioeconomic and acculturation factors in model 2; and
additionally for health insurance status in model 3. Our
rationale for variable selection was based on factors known to
influence the use of medications. ORs with 95% CIs were
computed. All statistical tests were 2-sided. No adjustments
were made for multiple comparisons. All analyses were
performed using SAS version 9.2 (SAS Institute).
Results
As depicted in Figure 1, 19.5% of eligible individuals
(N=14 914) were considered to be at high cardiovascular
risk. There were significantly more Puerto Rican adults (26%)
at high cardiovascular risk in comparison to the other
Hispanic/Latino groups, and this result corresponds to
previous findings.6 The distribution of participants at high
cardiovascular risk is included in Figure 1.
Participants
Table 1 depicts weighted estimates of the demographic and
socioeconomic characteristics of Hispanic/Latino partici-
pants at high cardiovascular risk. Mean age was 52 years
(95% CI 51.4–53.0), and of the 4136 participants included in
the sample, 54% were women. Approximately 33% (95% CI
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30.9–35.8) had more than a high school education, and 51%
(95% CI 48.0–53.0) had an annual family income of less than
$20 000. The majority of participants were married or living
with a partner (51%), 80% (95% CI 77.9–82.4) had resided in
the United States for >10 years, and Spanish was the
preferred language (83%). These sociodemographic charac-
teristics varied by Hispanic/Latino group.
Table 2 reports the prevalence of CVD and cardiovascular
risk factors and health care characteristics by Hispanic/
Latino group. The prevalence of CVD (prevalent CHD or
stroke) was 26% overall but ranged from 21% (Mexican
background) to 33% (Puerto Rican background). The preva-
lence of hypertension was 49% (95% CI 46.7–50.6) overall and
ranged from 39% (South American background) to 54%
(Dominican background). In addition, uncontrolled hyperc-
holesterolemia (untreated or treated, uncontrolled) was 43%
overall and varied by Hispanic/Latino background; it was
lowest in those with Dominican (34%) and Puerto Rican (39%)
backgrounds and highest in those with Central American
(50%) and Cuban (48%) backgrounds who were at high
cardiovascular risk.
Diabetes was the most prevalent cardiovascular risk factor,
affecting 60% (95% CI 58.2–62.5) of participants at high
cardiovascular risk. There was a statistically significant
(P<0.001) difference in diabetes prevalence among His-
panic/Latino background groups, ranging from 51% of
participants with a South American background to 68% of
participants with a Mexican background who were at high
cardiovascular risk. Obesity and smoking were significantly
more prevalent among participants with a Puerto Rican
background, 60% of whom were obese and 32% of whom were
current smokers.
Overall, 81% of participants were using at least 1
medication of any type. More than one-third of participants
(37%, 95% CI 34.7–39.5) were not insured, and that result
corresponds to national estimates of uninsured rates for the
Hispanic/Latino population in the United States. Neverthe-
less, there were statistically significant differences among
Hispanic/Latino groups, ranging from 12% of participants with
a Puerto Rican background to 53% of participants with a
Central American background who were uninsured. In addi-
tion, 32% of participants were publically insured with either
Medicare or Medicaid, and 23% had private insurance
coverage.
Differences in the Prevalence of Cardiovascular
Medication Use
Table 3 reports the estimated prevalence of statin and aspirin
use and their concurrent use among participants at high
cardiovascular risk by gender and Hispanic/Latino group.
Hispanic/Latino adults at high cardiovascular risk were more
likely to use aspirin (44%) than statins (25%), with 17%
concurrently using a statin and aspirin. There were significant
differences between Hispanic/Latino groups for both men
and women in the use of statins. Specifically, Puerto Rican
participants were significantly more likely to use statins (33%)
than other Hispanic/Latino groups, with the lowest preva-
lence in participants with a Central American background
(22%).
Among participants at high cardiovascular risk who were
aged ≥65 years, statin use was more prevalent (47%, 95% CI
42.0–51.2) overall than among those aged <65 years, with
significant differences among Hispanic/Latino background
groups for participants aged <65 years (Table 4). The
magnitude of these differences was statistically significant
and was similar to those presented in Table 3. Furthermore,
there were statistically significant differences among His-
panic/Latino groups among the insured overall. These
differences persisted in both age groups for both insured
and uninsured participants but, because of limited statistical
power, were not statistically significant.
Factors Associated With Differences in Statin Use
Table 5 displays the results of the bivariate and multivariate
analyses examining statin use among Hispanic/Latino partic-
ipants at high cardiovascular risk. Differences in statin use
between Hispanic/Latino background groups at high cardio-
vascular risk persisted after accounting for differences in age
and gender (model 1). Those from Puerto Rican and Domini-
can backgrounds who were at high cardiovascular risk had
significantly higher odds (OR 1.7 [95% CI 1.28–2.22] and OR
1.4 [95% CI 1.01–1.94], respectively) of using statins than
those from a Mexican background.
These differences in statin use persisted after controlling
for differences in socioeconomic and acculturation variables
(model 2) but were no longer statistically significant after
accounting for differences in health insurance coverage
(model 3). Specifically, differences in insurance coverage
substantially reduced the odds of statin use among those with
a Puerto Rican background (OR 1.3, 95% CI 0.97–1.75]) or a
Dominican background (OR 1.07, 95% CI 0.75,– 1.52]) who
were at high cardiovascular risk in comparison to their
Mexican counterparts. Participants with Cuban, Central
American, and South American backgrounds were equally
likely to use statins in comparison to those with a Mexican
background after accounting for differences in demographic
and cardiovascular risk factors.
We also examined the age-adjusted prevalence of statin
use for participants of Mexican and Puerto Rican backgrounds
by site and found no statistically significant differences. Statin
use, for example, among participants with a Mexican back-
ground who were at high cardiovascular risk was 24.6% (95%
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CI 21.1–28.0) in Chicago and 23.0% (95% CI 18.6–27.5) in
San Diego.
Differences in the Prevalence of Statin and
Aspirin Use Among Adults at High Cardiovascular
Risk With and Without Prevalent CVD
Figure 2 displays the prevalence of statin and aspirin use and
their concurrent use among participants at high cardiovascu-
lar risk with (n=939) and without (n=3197) prevalent CVD.
Overall, 33% of participants with prevalent CVD were using
statin medications and 51% were using aspirin. Although there
were notable differences in statin use and aspirin use across
Hispanic/Latino background groups, these differences were
not statistically significant.
Overall, 23% of participants at high cardiovascular risk
without prevalent CVD were using a statin, and 42% were
using aspirin. There was a statistically significant difference
in the prevalence of statin use by Hispanic/Latino back-
ground group (P<0.001). Those with a Central American
background were the least likely to use statins (17%), and
those with a Puerto Rican background who were without
CVD but at high cardiovascular risk were the most likely to
report the use of statins (32%). These differences persisted
in both men and women (data not shown). We found no
significant difference in the prevalence of aspirin use by
Hispanic/Latino background groups among participants
without prevalent CVD.
Discussion
To our knowledge, this study is the first to document
variations in the use of statins and aspirin among the diverse
Hispanic/Latino population in the United States. We found
that among Hispanic/Latino adults at high risk of CVD, 25%
used statins and less than half (44%) used aspirin. Despite
evidence that demonstrates clinical benefits for the primary
and secondary prevention of CVD, our findings indicated
substantial underuse of statins, particularly for the primary
prevention of CVD, among the growing Hispanic/Latino
population in the United States.
We also found that adults with Puerto Rican and Dominican
backgrounds who were at high cardiovascular risk were
significantly more likely than other Hispanic/Latino back-
ground groups, including those with a Mexican background, to
use these cardiovascular medications. These disparities were
not related to differences in cardiovascular risk profiles or
socioeconomic or acculturation factors, including language
preference, but rather were associated with differences in
health insurance. These findings suggest that certain His-
panic/Latino background groups may encounter more barri-
ers than others in accessing prescription medications. Recent
efforts through the Patient Care and Affordable Care Act to
expand insurance coverage11 may contribute to improve-
ments in the use of statins and ultimately lead to prevention
of CVD within the growing Hispanic/Latino population in the
United States.
Table 3. Prevalence of Cardiovascular Medication Use Among Participants at High Cardiovascular Risk Overall and by Hispanic/
Latino Group (Age-Adjusted)
Participants, % (95% CI)
All (n=4136) Mexican (n=1620) Cuban (n=558) Puerto Rican (n=944) Dominican (n=410)
Central American
(n=395)
South American
(n=209)
Statin use
Overall§ 25.4 (23.8–27.1) 23.5 (20.4–26.6) 22.2 (18.2–26.2) 32.9 (29.7–36.2) 28.3 (24.2–32.4) 20.0 (14.7–25.2) 22.4 (15.7–29.1)
Men† 25.9 (23.0–28.8) 24.3 (19.0–29.5) 21.9 (15.9–27.8) 32.2 (26.6–37.8) 31.8 (24.1–39.4) 17.9 (10.5–25.2) 32.0 (19.6–44.4)
Women‡ 24.9 (22.7–27.2) 22.8 (18.8–26.7) 22.5 (16.1–29.0) 33.5 (28.6–38.3) 25.8 (20.2–31.4) 21.6 (14.4–28.8) 17.1 (9.9–24.3)
Aspirin use
Overall 44.0 (41.9–46.2) 42.7 (38.9–46.4) 42.0 (37.3–46.6) 47.2 (43.1–51.3) 48.0 (41.7–54.3) 42.0 (35.7–48.3) 42.9 (34.5–51.3)
Men 44.7 (41.4–47.9) 42.9 (37.1–48.7) 43.4 (36.6–50.2) 45.1 (37.9–52.2) 53.8 (45.5–62.1) 42.2 (31.5–52.9) 48.3 (34.3–62.4)
Women 43.6 (40.8–46.4) 42.7 (37.5–47.9) 40.5 (34.5–46.6) 49.3 (44.0–54.5) 43.9 (36.1–51.7) 41.9 (33.9–49.9) 40.0 (29.8–50.2)
Concurrent aspirin and statin use
Overall§ 17.4 (15.9–18.9) 16.3 (13.8–18.8) 13.1 (9.5–16.8) 22.8 (19.8–25.7) 19.7 (15.9–23.6) 16.1 (10.9–21.2) 17.0 (11.0–23.0)
Men 18.1 (15.5–20.7) 17.0 (12.5–21.5) 14.1 (8.7–19.5) 20.5 (16.2–24.7) 25.7 (18.3–33.0) 16.3 (9.0–23.5) 26.3 (13.9–38.7)
Women‡ 16.7 (14.9–18.6) 15.7 (12.6–18.9) 12.2 (7.0–17.4) 24.8 (20.1–29.6) 15.5 (10.9–20.2) 16.0 (8.7–23.2) 11.9 (6.1–17.6)
Values were weighted for survey design and nonresponse and adjusted for age.
†P<0.05.
‡P<0.01.
§P<0.001.
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Our findings from the HCHS/SOL suggest that prior
research that primarily classified Hispanic/Latino participants
as a single group may underestimate disparities in the use of
preventative cardiovascular medications within the diverse
Hispanics/Latino population currently living in the United
States.7,8 In contrast to a previous study7 indicating that
46% of Hispanics/Latino and 38% of black participants at
high cardiovascular risk use statins compared with 50% of the
non-Hispanic white population, our findings demonstrated
variations in statin use within the diverse US Hispanic/Latino
population at high cardiovascular risk, particularly for the
primary prevention of CVD, for which statin medications are
indicated.
Although prior analyses reported racial and ethnic dispar-
ities in the use of aspirin,7 we found no such differences
within the Hispanic/Latino population at high cardiovascular
risk. This was true for aspirin use for both primary and
secondary prevention of CVD. In fact, more than half (51%) of
Hispanic/Latino participants with prevalent CVD were using
aspirin—a medication that can be obtained without a
prescription at a fraction of the cost—whereas only 33%
were using a statin (which is available only by prescription).
These findings suggest that addressing cost and access
barriers to the use of prescription medications (versus
nonprescription) is particularly important for the US His-
panic/Latino population.
We also evaluated differences in statin use by Hispanic/
Latino background that suggest, in contrast to our finding
on aspirin use, variation in the use of statins among adults
at high cardiovascular risk within the Hispanic/Latino
population. These differences were particularly pronounced
among those without prevalent CVD. Of note, 32% of
participants with a Puerto Rican background versus 17% and
21% of those with Central American and Mexican back-
grounds, respectively, at high cardiovascular risk used
statins for the primary prevention of CVD. Participants with
Central American and Mexican backgrounds who were at
high cardiovascular risk were more likely to have uncon-
trolled (untreated or treated) hypercholesterolemia (50%)
and diabetes (68%), respectively, both of which are leading
risk factors for CVD. Improving access to and use of statins
among the Hispanic/Latino population, particularly back-
ground-specific groups most at risk for underuse, is critical
for efforts aimed at reducing the burden of CVD and should
be a public health priority. These efforts are particularly
important considering recent American College of Cardiology
and American Heart Association guidelines2 that recom-
mend treatment with statins for both primary and secondary
prevention of CVD.
Our study suggests that policies and interventions to
reduce disparities in the use of preventive cardiovascular
medications within the diverse Hispanic/Latino population
must address barriers to accessing health insurance.
Although recent implementation of the Affordable Care Act,
which sought to improve health insurance coverage, is
promising11—with evidence that uninsured rates among
Hispanic/Latino adults declined to 23% in 2014 compared
with 36% in 201312—there is significant variation at the state
level. Of note, >33% of Latino/Hispanic adults living in states
that have not expanded Medicaid (eg, Texas) remain unin-
sured compared with an uninsured rate of 17% among those
living in states (eg, Illinois) that have implemented Medicaid
expansion.12 Consequently, Medicaid expansion may con-
tribute to improvements in insurance coverage and thus statin
Table 4. Prevalence of Statin Use Among Participants at High Cardiovascular Risk by Hispanic/Latino Group According to Age
Group and Insured Status
Participants, % (95% CI)
All (n=4136) Mexican (n=1620) Cuban (n=558) Puerto Rican (n=944) Dominican (n=410)
Central American
(n=395)
South American
(n=209)
Aged ≥65 y 46.6 (42.0–51.2) 39.0 (29.5–48.5) 48.7 (39.8–57.5) 52.4 (44.5–60.3) 51.4 (37.3–65.4) 41.7 (22.8–60.7) 35.6 (17.7–53.6)
Aged <65 y§ 19.5 (17.8–21.3) 16.5 (13.3–19.6) 16.3 (12.4–20.3) 28.5 (24.3–32.6) 21.3 (17.0–25.6) 13.7 (9.3–18.2) 20.5 (13.5–27.6)
Insured
Overall§ 34.0 (31.5–36.5) 28.0 (23.1–32.9) 43.5 (37.0–49.9) 36.0 (31.7–40.3) 31.8 (25.7–37.8) 28.3 (19.9–36.8) 26.5 (16.3–36.7)
Aged ≥65 y 51.5 (46.4–56.6) 47.0 (35.5–58.4) 53.6 (44.3–63.0) 53.1 (44.6–61.7) 54.9 (39.1–70.6) 46.0 (25.4–66.6) 39.2 (18.3–60.1)
Aged <65 y 26.5 (24.0–29.0) 22.7 (17.9–27.6) 30.3 (22.1–38.6) 30.8 (26.2–35.4) 24.8 (19.5–30.0) 21.5 (13.2–29.8) 21.5 (10.1–32.8)
Uninsured
Overall 11.4 (9.1–13.8) 11.9 (8.2–15.7) 8.5 (3.8–13.2) 14.7 (7.2–22.2) 12.3 (3.8–20.8) 9.5 (4.4–14.6) 20.8 (11.7–29.9)
Aged ≥65 y 16.9 (4.8–29.0) 14.6 (0.0–30.3) 20.6 (0.0–48.4) 0 6.9 (0.0–21.5) 16.1 (0.0–40.3) 24.9 (0.0–50.4)
Aged <65 y 11.0 (8.7–13.2) 11.8 (7.9–15.6) 6.9 (3.2–10.7) 15.2 (7.5–22.9) 12.8 (3.7–21.8) 8.5 (4.1–12.8) 20.2 (10.8–29.6)
Values were weighted for survey design and nonresponse and adjusted for age.
§P<0.001.
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Table 5. Sociodemographic, Acculturation, and Health Care Factors Associated With Differences in Statin Use Among the
Hispanic/Latino Population at High Cardiovascular Risk
Unadjusted OR (95% CI)
Adjusted OR (95% CI)
Model 1 Model 2 Model 3
Hispanic/Latino group
Mexican Reference Reference Reference Reference
Cuban 1.64 (1.23–2.19)* 0.99 (0.73–1.34) 1.21 (0.89–1.66) 1.07 (0.77–1.49)
Puerto Rican 2.08 (1.60–2.71)* 1.69 (1.28–2.22)* 1.73 (1.30–2.31)* 1.30 (0.97–1.75)
Dominican 1.54 (1.12–2.13)* 1.40 (1.01–1.94)* 1.45 (1.04–2.02)* 1.07 (0.75–1.52)
Central 1.03 (0.67–1.58) 0.86 (0.57–1.29) 0.94 (0.63–1.40) 0.97 (0.64–1.46)
South American 1.28 (0.83–1.96) 1.18 (0.73–1.92) 1.19 (0.74–1.93) 1.13 (0.69–1.84)
Age, y
<57 Reference Reference Reference Reference
57–64 2.72 (2.13–3.46)* 2.47 (1.92–3.18)* 2.33 (1.80–3.02)* 2.25 (1.72–2.94)*
≥65 4.72 (3.71–6.01)* 4.52 (3.54–5.77)* 4.24 (3.29–5.47)* 3.12 (2.38–4.10)*
Gender
Women Reference Reference Reference Reference
Men 0.98 (0.79–1.23) 0.96 (0.76–1.22) 0.90 (0.71–1.13) 0.91 (0.71–1.16)
Number of CVD risk factors
0 or 1 Reference Reference Reference Reference
≥2 2.22 (1.77–2.79*) 2.05 (1.63–2.59)* 1.99 (1.58–2.51)* 2.08 (1.64–2.63)*
Prevalent CVD (CHD or stroke)
No Reference Reference Reference Reference
Yes 1.58 (1.27–1.98)* 1.56 (1.18, 1.82)* 1.62 (1.26–2.07)* 1.50 (1.16–1.95)*
Education
Less than high school Reference Reference Reference
High school 0.57 (0.45–0.73) 0.71 (0.54–0.91) 0.72 (0.55–0.93)
More than high school 0.78 (0.61–0.99) 0.94 (0.71–1.23) 0.94 (0.71–1.23)
Household income, $/year
<20 000 Reference Reference Reference
20 000–40 000 0.68 (0.54–0.86)* 0.82 (0.64–1.05) 0.89 (0.69–1.15)
40 000–75 000 0.83 (0.56–1.23) 1.08 (0.74–1.58) 1.07 (0.72–1.57)
>75 000 1.32 (0.71–2.43) 2.07 (0.99–4.32) 1.94 (0.82–4.58)
Language preference
English Reference Reference Reference
Spanish 1.21 (0.94–1.56) 1.24 (0.91–1.69) 1.36 (0.99–1.87)
Years in the United States
<5 Reference Reference Reference
5–10 1.99 (1.18–3.35)* 2.32 (1.35–4.00)* 2.10 (1.27–3.47)*
≥10 3.55 (2.41–5.21)* 3.16 (2.06–4.86)* 2.34 (1.58–3.47)*
Health insurance
No Reference Reference
Private 3.49 (2.60–4.68)* 2.53 (1.81–3.53)*
Public (Medicaid or Medicare) 4.84 (3.65–6.43)* 2.86 (2.10–3.89)*
Other 2.10 (1.32–3.33)* 1.74 (1.06–2.87)*
Missing 2.39 (0.87–6.54) 1.69 (0.69–4.14)
Model 1: adjusted for Hispanic/Latino group, age, gender, CVD status. Model 2: adjusted for all variables in model 1 plus education, income, language, Short Acculturation Scale for
Hispanics score, and number of years in the United States. Model 3: adjusted for all variables in model 2 and health insurance. Values were weighted for survey design and nonresponse.
CHD indicates coronary heart disease, CVD, cardiovascular disease; OR, odds ratio.
*P<0.05.
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use for some Hispanic/Latino groups but not others based on
state of residence. Future research should examine the
impact of the Affordable Care Act on disparities in access to
prescription medications, including statins, within the His-
panic/Latino population.
Limitations
Our analysis has several limitations. First, our definition of
high cardiovascular risk, including prevalent CVD, includes
self-reported information and lacks some variables used by
others when assigning cardiovascular risk (eg, Framingham
risk score). Second, although other prescription medications
may be used for the prevention of CVD, we focused on statins
and aspirin because they are first-line recommendations with
proven benefit for CVD and are currently used almost
exclusively for this purpose. Third, our measure of aspirin
use does not differentiate between aspirin used regularly for
CVD prevention and aspirin used for symptomatic treatment
as an analgesic. Fourth, the HCHS/SOL did not include any
other US racial or ethnic groups for comparison; however, the
findings for statin and aspirin use of the Hispanic/Latino
population in aggregate are similar to those found in other
national surveys.7 Finally, our analyses excluded 1501
participants with missing information. Compared with the
14 914 participants included in our analysis, these partici-
pants were less likely to be uninsured (40% versus 49%;
P<0.001) and were slightly younger (mean age 38 years
versus 41 years; P<0.001).
Conclusions
Among Hispanic/Latino adults of diverse backgrounds, statin
use—especially for the primary prevention of CVD—was
more prevalent in those with Puerto Rican and Dominican
backgrounds who were at high cardiovascular risk. Statin use
was associated with insurance coverage and may contribute
to future cardiovascular outcomes within the growing US
Hispanic/Latino population that is experiencing a growing
burden of CVD and CVD risk factors. Efforts to increase the
use of statins among Hispanic/Latino adults at high cardio-
vascular risk, particularly targeting at-risk groups such as
those with Mexican and Central American backgrounds,
should include improving access to health insurance cover-
age. Efforts to improve prescription of, access to, and use of
statins are particularly important.
Sources of Funding
The Hispanic Community Health Study/Study of Latinos was
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from the National Heart, Lung, and Blood Institute (NHLBI) to
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Figure 2. Prevalence estimates of cardiovascular medication use among adults at high cardiovascular risk with and without
prevalent cadiovascular disease by Hispanic/Latino group (age adjusted). *Statistically significant difference (P<0.05) in
prevalence of use across Hispanic/Latino groups. Values were weighted for survey design and nonresponse and were adjusted for
age. Error bars indicate 95% CI.
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